Sarah Boyce compensation by year
Atrium Therapeutics Summary Compensation Table · all 3 fiscal years held| Component | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
| Salary | $601,400 | $634,500 | $659,900 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $0 | $2,766,000 | $10,748,480 |
| Option awards | $4,319,275 | $7,374,840 | $2,157,090 |
| Non-equity incentive | $430,100 | $349,000 | $594,000 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $15,336 | $15,379 | $17,010 |
| Total | $5,366,111 | $11,139,719 | $14,176,480 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Atrium Therapeutics, Inc. DEF 14A filed April 29, 2025, accession 0001599901-25-000092, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Atrium Therapeutics, Inc. filed document, accession 0001599901-25-000092. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 234,000 | $6,804,720 | — |
| RSU | 62,500 | $1,817,500 | — |
| RSU | 37,500 | $1,090,500 | — |
| Option | 208,334 | — | $22.47 |
| Option | 137,500 | — | $6.57 |
| Option | 6,250 | — | $22.34 |
| Option | 115,105 | — | $14.22 |
| Option | 231,250 | — | $10.16 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Atrium Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
2 Form 4 lines since the FY2024 proxy (filed April 29, 2025)current to 2026-11-06 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-09-18 | Tax withholding | — | 126,418 | $8.95 | 138,668 |
| 2026-02-27 | Grant or award derivative | — | 20,000 | $0.00 | 20,000 |
The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Atrium Therapeutics’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Sarah Boyce · this page | President and Chief Executive Officer | $14,176,480 |
| John Moriarty | Chief Legal Officer and Corporate Secretary | $9,699,196 |
| Michael MacLean | Chief Financial Officer | $4,941,722 |
| W. Michael Flanagan | Chief Scientific Officer | $4,802,896 |
| Teresa McCarthy | Chief Human Resources Officer | $4,622,733 |
Board service
Atrium Therapeutics board · FY2024How this board is paid
Company policy: Atrium Therapeutics pays directors a $40,000 cash retainer and $375,000 in equity. As stated in Atrium Therapeutics's FY2024 proxy.
The full Atrium Therapeutics compensation record
free company briefThis page is one person within Atrium Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Atrium Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Atrium Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Atrium Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order RNA
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.